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bjectives We investigated the time course of stent patency in the femoro-popliteal artery for as
ong as 4 years.
ackground Stent fracture has been related to poor 2-year patency in the femoro-popliteal artery.
ethods We studied 239 consecutive patients who underwent provisional de novo stenting with
itinol stents for 333 limbs (Luminexx stent [C. R. Bard, Inc., Murray Hill, New Jersey] in 91 limbs;
mart stent [Cordis Corp., Miami Lakes, Florida] in 242 limbs) from April 2004 to December 2007.
tent fracture was determined by X-ray with multiple projections. Patency was assessed by duplex
ltrasonography as peak systolic velocity ratio 2.4 or by angiography (% diameter stenosis 50%).
rimary patency in those with and without stent fracture at follow-up was assessed along with fac-
ors inﬂuencing stent fracture.
esults Primary patency was 81%, 74%, 68%, and 65% at 1, 2, 3, and 4 years, respectively. Stent
racture occurred in 14% (78 of 544) per stent and 17% (55 of 333) per limbs. Stent fracture was
igniﬁcantly associated with multiple stent deployments (with fracture  2.3  0.9 stents vs. with-
ut fracture  1.5  0.7 stents, p  0.001) and long lesions (with fracture  208  84 mm vs.
ithout fracture  121  79 mm, p  0.001). Primary patency was 68% with fracture versus 83%
ithout fracture at 1 year, p  0.03; 65% versus 75% at 2 years, p  0.05; 61% versus 69% at 3
ears, p  0.06; and 61% versus 65% at 4 years, p  0.07. Neither type 1 nor type 3 fracture af-
ected patency, although type 2 showed the worst patency.
onclusions Stent fracture worsened the patency during the ﬁrst 2 years, but it did not
pparently affect patency beyond 2 years. In particular, complete stent separation did not affect
atency. (J Am Coll Cardiol Intv 2009;2:665–71) © 2009 by the American College of Cardiology
oundation
rom the Kansai Rosai Hospital, Hyogo, Japan.anuscript received September 9, 2008; revised manuscript received February 19, 2009, accepted April 19, 2009.
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666he technical and clinical success rates of the endovascular
herapy (EVT) for the stenotic and occlusive lesions in the
emoro-popliteal artery (FPA) have reached over 95% due
o the improvements of new generation devices (1,2).
ong-term patency, however, remains as an unsolved issue.
alloon angioplasty alone in the FPA demonstrated low
rimary patency rates of 40% to 60% after 6 to 12 months
3,4) depending on the clinical stages, lesion severity, and
un-off in below-the-knee arteries (1,2). Early experiences
ith stainless-steel stents showed no beneficial efficacy on
he primary patency compared with angioplasty alone (5,6).
ccordingly, in the TransAtlantic Inter-Society Consensus
TASC) 2000, stenting was relegated to a bailing-out
rocedure in the event of failed balloon angioplasty (1).
Recently, nitinol stents have been introduced, which have
emonstrated superior primary patency to balloon angio-
lasty (7,8) or to steel stents (9) in the superficial femoral
rtery (SFA). Hence, EVT with nitinol stents has become
idely applied in the FPA lesion. Despite the improved
rimary patency, however, stent fracture after deployment of
itinol stents has been recognized as an adverse event in
the FPA, where the mechanical
factors, such as external forces,
vessel compression, torsion, and
elongation. Stent fracture was
considered as a risk of in-stent
restenosis and reocclusion in the
SFA stenting in the chronic
phase (10), just as it was sug-
gested to be a cause of restenosis
in the coronary artery (11).
Nonetheless, in our clinical
practice experience, stent frac-
ure does not always result in restenosis in the FPA.
lthough the 2-year patency with and without stent fracture
n the FPA has been documented earlier (10), the time
ourse of patency with and without stent fracture beyond 2
ears remains unknown. Thus, in this study, we sought to
nvestigate the patency after nitinol stenting in the FPA in
elation to stent fracture and fracture morphology over a
-year period.
ethods
atients. We retrospectively analyzed a patient database
rospectively maintained from April 2004 to December
007 that included the 239 consecutive patients who suc-
essfully underwent EVT for de novo FPA lesions with
rovisional nitinol stenting in 333 limbs, and who also gave
onsent to receive follow-up ultrasound and X-ray in the
ardiovascular Division of Kansai Rosai Hospital. All
atients had symptoms due to FPA lesions (Rutherford
tage 2 to 6) that affected the quality of life in spite of excises
bbreviations
nd Acronyms
VT  endovascular therapy
PA  femoro-popliteal
rtery
FA  superficial femoral
rtery
ASC  TransAtlantic Inter-
ociety Consensusnd medications. We excluded those presenting with acute Ir subacute limb ischemia with nitinol stents previously
eployed in the FPA, and those who underwent stenting in
he restenotic lesions. We developed the study protocol in
ccordance with the Declaration of Helsinki, and it was
pproved by the ethics committee of Kansai Rosai Hospital.
ll patients gave written informed consent.
rotocols. After the initial diagnostic angiograms of the
ower limb, the indication of EVT was judged by consulting
ith vascular surgeons. Indication of EVT for the FPA
esions included 70% of vessel diameter stenosis without
nflow lesions. Approaches for EVT in the FPA lesions
ere determined by the operator’s discretion. In general,
fter a 6-F sheath insertion, either a 0.035- or a 0.014-inch
ire was advanced into the lesion; unfractionated heparin
5,000 U) was injected into the artery. The lesion was
xpanded using an optimal balloon for 60 s. A nitinol stent
as implanted in accordance with the American College of
ardiology/American Heart Association guidelines in pa-
ients presenting with a residual pressure gradient 10 mm
g, residual stenosis30%, and/or flow-limiting dissection
fter balloon dilation. Self-expandable stents with the di-
meter approximately 2-mm larger than the reference di-
meter were used. Stents of 8 mm in diameter were used in
ost cases. Selection of stents was dependent on the terms:
uminexx stents (Bard, Inc., Murray Hill, New Jersey) were
sed from April 2004 to December 2005, and mean
ollow-up duration was 28  19 months; Smart stents
Cordis Corp., Miami Lakes, Florida) were used from
anuary 2006 to December 2007, and mean follow-up
uration was 17  9 months. Dual antiplatelet therapy
aspirin 100 mg/day, ticlopidine 200 mg/day, or cilostazol
00 mg/day) was started at least 1 week before EVT and
ontinued until the end of follow-up.
ollow-up and outcomes. Clinical evaluations including
ymptom changes, ankle brachial index, lesion patency
valuated by ultrasound, and stent fracture assessed by X-ray
ere performed at baseline, approximately at 24 h, 72 h, 1
onth, and at every 3 months after procedure. Primary
atency was defined as peak systolic velocity ratio 2.4 by
uplex ultrasound (12). Stent fracture was defined as clear
nterruption (1 to 2 mm) of stent struts identified by
-ray from 4 projections, with resulting kink or misalign-
ent along the axial length of the stent. Morphology of the
tent fracture was classified based on Appendix A: the Viva
hysicians, Inc., Research Program of Rocha-Singh et al.
13). In brief, a single-tine fracture was defined as type 1;
ultiple-tine fractures, type 2; stent fracture(s) with pre-
erved alignment of the components, type 3; stent frac-
ure(s) with mal-alignment of the components, type 4; stent
racture(s) in a trans-axial spiral configuration, type 5. An
-ray from 4 projections was performed at each follow-up
eriod to evaluate the stent fracture by 2 observers who had
he experience of more than 500 EVT cases within a year.
f different grades of stent fracture were observed within a
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667tent, the severest grade was adopted. Bent knee radiogra-
hy was not performed. The outcomes of this study were
verall primary patency, patency associated with and with-
ut stent fracture, patency according to the types of nitinol
tents, and the morphology of stent fracture during the
ollow-up period.
tatistical analysis. Statistical analysis was performed using
PSS (SPSS Inc., Chicago, Illinois). Data are shown as
ean  standard deviation. Unpaired t test was used to
ompare the continuous variables between the groups, and
hi-square test was used to compare ratios between the
roups, with the statistical significance level set at a value of
 0.05. Primary patency was determined with Kaplan-
eier survival analysis and compared by log-rank testing.
Table 1. Patient Characteristics
Overall
(n  239)
Age (yrs) 74  9
Men 72% (171)
Body mass index 22  2.8
Risk factors
Hypertension 99% (236)
Hyperlipidemia/LDL (mg/dl) 41% (98)/111 33
Diabetes mellitus/HbA1c (%) 64% (153)/6.4 1.1
Smoking (current) 29% (69)
Chronic renal failure on dialysis 22% (53)
Coronary artery disease 53% (127)
Cerebrovascular disease 38% (91)
Data are presented as mean SD or (%) n.
HbA1c glycosylated hemoglobin; LDL low-density lipoprotein.
Table 2. Lower Limb and Lesion Characteristics
Overall
(n  333)
ABI 0.61  0.23
Rutherford classiﬁcation 3.3  1.1
Claudicators/critical limb ischemia 71% (237/333)/29% (96/333)
TASC II classiﬁcation
A 135
B 56
C 44
D 98
Chronic total occlusion 43% (143)
Lesion length, mm 135  86
Lesion calciﬁcation 41% (138)
Number of runoff vessels
0 28
1 104
2 142
3 59
Data are presented as mean SD or (%) n.ABI ankle brachial index; TASC TransAtlantic Inter-Society Consensus.esults
atients. Patient characteristics are shown in Table 1.
here were no significant differences in patient character-
stics including atherosclerosis risk factors between those
ith and without stent fracture. During follow-up, 13% (30
f 239) of patients died, and 10 limbs were amputated in 9
atients.
ower limb and lesion characteristics. Lower limb and lesion
haracteristics are shown in Table 2. Lesions involving
alcification were defined by angiography as readily visible
ensities noted within the apparent vascular wall. Those
howing stent fracture involved less critical limb ischemia,
nd lower Rutherford stages than those not showing stent
tent Fracture ()
(n  43)
Stent Fracture ()
(n  196) p Value
74  9 74  9 0.68
67% (29) 72% (142) 0.51
22  2.3 22  2.9 0.94
98% (42) 99% (194) 0.49
47% (20)/114 32 40% (78)/110 33 0.17
58% (25)/6.2 1.0 65% (128)/6.4 1.1 0.38
35% (15) 28% (54) 0.34
23% (10) 22% (43) 0.85
53% (23) 53% (104) 0.96
42% (18) 37% (73) 0.57
tent Fracture ()
(n  55)
Stent Fracture ()
(n  278) p Value
0.56  0.22 0.62  0.24 0.27
3.0  0.7 3.3  1.2 0.029
% (48/55)/13% (7/55) 68% (189/278)/32% (89/278) 0.0039
0.001
5 130
7 49
6 38
37 61
75% (41) 37% (102) 0.001
208  84 121  79 0.001
36% (20) 42% (118) 0.40
0.07
2 26
16 88
21 121
16 43SS
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668racture. Lesions associated with stent fracture included
ore severe forms of TASC classification, longer lesion
ength, and more frequent chronic total occlusions than the
esions without stent fracture.
ntervention procedure. The intervention procedure is
hown in Table 3. Four hundred and seven Smart stents
ere used in 242 limbs, and 137 Luminexx stents were used
n 91 limbs. Stent fracture occurred in 14% (78 of 544) of
tents, and 17% (55 of 333) of limbs during the follow-up.
etween the different types of nitinol stents, Smart stents
howed less fracture rate (13%, 31 of 242) than Luminexx
Figure 1. Primary Patency per Limb in 333 Limbs in Patients Who Underwe
With Nitinol Stents
Table 3. Intervention Procedure
Overall
(n  333)
Antegrade access/crossover access/popliteal access 51% (171)/35% (117)/14%
Implantation of stent
Luminexx (C. R. Bard, Inc., Murray Hill,
New Jersey)/Smart (Cordis Corp.,
Miami Lakes, Florida)
27% (91)/73% (242)
Number of stents
1 57% (190)
2 24% (81)
3 17% (56)
4 2% (6)
Data are presented as (%) n.Patency decreased in the ﬁrst 2 years, but it did not apparently changed beyond 2 ytents (26%, 24 of 91, p  0.003). The number of stents
sed per vessel was greater in those with stent fracture than
n those without fracture.
orphology of the stent fracture. Morphology of the stent
racture was as follows: type 1 in 10 limbs, type 2 in 32
imbs, and type 3 in 13 limbs. None of the patients had type
nor type 5 stent fracture.
utcomes. Overall primary patency per limb is shown in
igure 1. The primary patency remained 65% at 4 years.
rimary patency in those associated with stent fracture and
n those without stent fracture is shown in Figure 2. Primary
dovascular Therapy for De Novo Lesions in the Femoro-Popliteal Artery
Stent Fracture ()
(n  55)
Stent Fracture ()
(n  278) p Value
27% (15)/35% (19)/38% (21) 56% (156)/35% (98)/9% (24) 0.001
43% (24)/56% (31) 24% (67)/76% (211) 0.003
0.001
20% (11) 64% (179)
33% (18) 23% (63)
42% (23) 12% (33)
5% (3) 1% (3)nt En(45)ears. SE  standard error.
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669atency was worse in those associated with stent fracture
han in those without stent fracture at 1 year (68% with
racture vs. 83% without fracture, p  0.03), but it was not
ignificantly different between the groups beyond 2 years
65% vs. 75% at 2 years, p  0.05; 61% vs. 69% at 3 years,
 0.06; and 61% vs. 65% at 4 years, p  0.07). Primary
atency with and without stent fracture in terms of different
ypes of nitinol stents was also evaluated. Primary patency of
he Luminexx stent with and without stent fracture was 61%
ersus 84% at 1 year, p  0.04; 61% versus 80% at 2 years,
 0.05; 56% versus 75% at 3 years, p  0.08; and 56%
ersus 70% at 4 years, p  0.09. Primary patency of the
mart stent with and without stent fracture was 75% versus
3% at 1 year, p 0.26; and 69% versus 71% at 2 years, p
.26. Types of nitinol stents did not affect the primary
atency during follow-up. The effects of stent fracture
orphology on the primary patency are shown in Figure 3.
lthough type 2 (multistrut) stent fracture revealed poor
utcomes (p  0.01), neither type 1 (single strut, p  0.68)
or type 3 (complete separation, p  0.18) affected the
rimary patency compared with those without stent fracture.
iscussion
f 544 nitinol stents implanted in 333 limbs, stent fracture
ccurred in 14% (78 of 544) of stents, and in 17% (55 of
Figure 2. Primary Patency per Limbs in Those Associated With and Withou
Although the study lacks statistical power to conﬁrm, stent fracture unlikely af33) of limbs during the follow-up period of 4 years. wrimary patency was 81%, 74%, 68%, and 65% at 12, 24, 36,
nd 48 months, respectively, which was similar to earlier
tudies (8,9). Stent fracture was associated with long lesions,
nd was also associated with the number of stents used.
tent fracture worsened the patency during the first 2 years,
ut did not apparently affect the patency beyond 2 years.
lthough type 2 stent fracture revealed poor outcomes,
either type 1 nor type 3 stent fracture affected the primary
atency compared with those without stent fracture.
Nitinol stents have become widely applied not only in the
imple TASC A and B lesions, but also in the complex
ASC C and D lesions in the FPA (14,15). There is
ncreasing evidence that patency of nitinol stents is superior
o those of early metallic stents, and to balloon angioplasty
lone (7–9). Improvement in long-term patency by using
itinol stents was expected. Earlier reports, however, sug-
ested long lesion length and a large number of nitinol
tents were the predictors of nitinol stent fracture in the
PA, and subsequently resulted in stent failure in the
hronic phase (10). We have also reported that vigorous
xercise adversely affected stent fracture in patients im-
lanted with nitinol stents in the SFA (16). The findings
hat claudicaton was more prevalent in those with stent
racture than in those without fracture in this study and that
tent fracture was significantly associated with long lesions
t Fracture
patency beyond 2 years. SE  standard error.t Stenere compatible with these previous observations.
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670Although long-term patency with respect to stent frac-
ure after EVT is a clinically important issue, none of the
arlier studies have addressed the prognosis beyond 2 years.
his study is the first to investigate the outcomes of stent
racture beyond 2 years in the new nitinol stent era in
elation to the morphology of stent fracture in a single
enter experience using only nitinol stents.
The incidence of stent fracture in this study was appar-
ntly lower than that observed in the FESTO (FEmoral
Tenting in Obstructions) trial (10). This may be attributed
o the differences in life-styles and physique in the Eastern
opulation. In fact, body mass index in patients included in
his study was approximately 22 kg/m2. It may be interest-
ng to speculate that stent fracture is adversely affected by
he muscle volume through compression and expansion
echanisms. Alternatively, underestimation of stent frac-
ure may occur in severely calcified lesions, where the stents
ended to be underexpanded.
tudy limitations and weaknesses. This study uses a retro-
pective and nonrandomized analysis in spite of using a
rospectively maintained database and lack of sufficient pa-
ients followed in a single center. Only 2 types of nitinol stents
Figure 3. Comparison of Primary Patency per Limbs Among Those Showing
Compared with the nonfracture group (type 0), type 2 stent fracture revealed
the primary patency. SE  standard error.ere used in this study, which were the only nitinol stents Tvailable for clinical use in Japan. The difference in the
tructure of segments and number of connecting bridges
etween these 2 stents may be responsible for the different
tent fracture rate and the patency. Further investigation is
eeded using new generation stents in the future.
It is interesting to speculate that there may be a difference in
he outcomes depending on the morphology of stent fracture.
enign stent fracture may include type 1 and 3 fractures, and
otentially harmful stent fracture includes type 2.
onclusions
tent fracture worsened the patency during the first 2 years,
ut it did not apparently affect patency beyond 2 years,
lthough the study lacked statistical power to confirm this.
large-scale, multicenter, prospective study on this subject
s warranted based on the results of this study.
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